|Bid||6.11 x 4000|
|Ask||6.61 x 4000|
|Day's Range||6.32 - 6.83|
|52 Week Range||3.21 - 9.36|
|Beta (5Y Monthly)||0.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2024 - Mar 01, 2024|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.42|
Subscribe to Yahoo Finance Plus to view Fair Value for IOVA
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were jumping 10.9% higher as of 11:49 a.m. ET on Monday. The nice gain came after Goldman Sachs initiated coverage on Iovance stock with a buy recommendation. Investors no doubt liked Goldman Sachs' 12-month price target of $12 for Iovance.
SAN CARLOS, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on November 16, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 59,950 shares of Iovance’s common stock to nine new non-executive employees. The awards